Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Rationale for 10-day decitabine with venetoclax for high-risk AML

Abhishek Maiti • 1 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Decitabine Venetoclax

Abhishek Maiti, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale behind a Phase II study investigating venetoclax and decitabine for relapsed/refractory acute myeloid leukemia (AML) patients (NCT03404193). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Abhishek Maiti

ADVENT-AML trial: azacitidine, venetoclax, and allogeneic NK cells in R/R AML 3:52
ADVENT-AML trial: azacitidine, venetoclax, and allogeneic NK cells in R/R AML
Abhishek Maiti • 9 Sep 2025
γ9δ2 T-cell activation with ICT01 and azacitidine-venetoclax in patients with newly diagnosed AML 6:45
γ9δ2 T-cell activation with ICT01 and azacitidine-venetoclax in patients with newly diagnosed AML
Abhishek Maiti • 10 Sep 2025
Venetoclax with decitabine for high-risk AML and MDS 2:05
Venetoclax with decitabine for high-risk AML and MDS
Abhishek Maiti • 2 Jun 2020
Comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in AML based on fitness 9:17
Comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in AML based on fitness
Abhishek Maiti • 2 Jun 2020

Related Videos

Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia 1:48
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia
Michael Savona • 6 Dec 2025
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML 1:31
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen • 6 Dec 2025
The development and international validation of an unsupervised classification model in AML 1:28
The development and international validation of an unsupervised classification model in AML
Amin Turki • 7 Dec 2025
The potential association of plasma venetoclax level with treatment efficacy in first-line AML 2:08
The potential association of plasma venetoclax level with treatment efficacy in first-line AML
Thomas Cluzeau • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals